Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings. We are at the beginning of an era in which waste of resources may be reduced by scientific analysis with improvement in patient care and teaching achieved as a result.
RodehefferR.J., JacobsenF.J., GershB.J.The incidence and prevalence of congestive heart failure in Rochester, Minnesota.Mayo Clin Proc1993; 68: 1143–50
2.
ReitsmaJ.B., MosterdA., KosterR.W., van CapelleF.J., GrobbeeD.E., TijssenJ.G.. Increase in the number of admissions due to heart failure in Dutch hospitals in the period 1980-1992.Ned Tijdschr Geneeskd1994; 138: 866–71
3.
KleberF.X., NiemöllerL., DoeringW.. Impact of converting enzyme inhibition on progression of chronic heart failure. Results of the Munich Mild Heart Failure Trial.Br Heart J1992; 67: 289–96
4.
MunozE., ChalfinD., BirnbaumE., MulloyK., JohnsonH., WiseL.. Hospital costs, resource characteristics, and the dynamics of death for patients with a primary diagnosis of congestive heart failure.N Y Stat J Med1989; 89: 60–3
5.
KleberF.X., NiemöllerL., DoeringW.. Sozio-okonomische Bedeutung der ACE-Hemmer-Therapie bei Frühformen der Herzinsuffizienz.Münch Med Wschr1992; 134: 749–52
6.
SeilerR.H., LobleyM.. Efficient diagnosis of common complaints: a comparative study in the United States and England, j Tarn Praa1991; 33: 41–6
7.
KulickD.L., RahimtoolaS.H.. Risk stratification in survivors of acute myocardial infarction: routine cardiac catherization and angiography is a reasonable approach in most patients.Am Heart J1991; 121: 641–56
8.
ChapekisA.T., BurekK., TopolE.J.. The cost: benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis.Am Heart J1989; 118: 878–82
9.
LindsayH.S.J., HollA.S., MorrisJ.L., ZamanA.G., CowanJ.C.. Strategies of ACE-Inhibition following myocardial infarction: costs and benefits. [Abstract]Eur Heart J1994; 15(Suppl): 328
10.
The Captopril-Digoxin Multicenter Research Group.Comparative effects of therapy with Captopril and digoxin in patients with mild to moderate heart failure.JAMA1988; 259: 539–44
11.
PackerM., GheorghiadeM., YoungJ.B.for the RADIANCE Study. Withdrawal of digoxin for patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors.N Engl J M1993; 329: 1–7
12.
WardR.E., GheorghiadeM. on behalf of the RADIANCE, and PROVED Investigative Groups. The economic outcomes of withdrawal of digoxin therapy in adult patients with stable heart failure: a decision analysis. [Abstract].Circulation1992; 86: 1–101
13.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK on behalf of the PROVED Investigative Group.Randomized study assessing the effect of digoxin withdrawal in patients with mild and moderate chronic congestive heart failure: results of the PROVED Trial.JACC1993; 22: 955–62
14.
The SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure.N Engl J Med1991; 325: 293–302
15.
JonssonB.. Improving patient care: consequences for resource allocation.Cardiology1994; 84: 420–6
16.
CohnJ.N., JohnsonG., ZiescheS.A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. (V-HeFT II).N Engl J Med1991; 325: 303–10
17.
PaulS.D., KeaneyK.M., EagleK.A., WeinsteinM.C.. The costs and the effectiveness of angiotensin converting enzymne inhibition in patients with congestive heart failure.Circulation1992; 86: Abstracts 1-101
18.
Hout vanB.A., WielinkG., BonselG.J., RuttenF.F.H.. Effects of ACE Inhibitors on Heart Failure in the Netherlands A Pharmacoeconomic Model.PharmacoEconomics1993; 3: 387–97
19.
TedderM., AnstadtM.P., WhartonJ.M., RevishviliA.S., HegdeS.S., LoweJ.E.. Prophylactic implantable defibrillator patches in patients at high risk for malignant ventricular dysrhythmias.ASAIO J1992; 38: M261–5
20.
LoisanceD., BenvenutiC., LebrunT., LedereA., TarralA., SaillyJ.C.. Cost and cost effectiveness of the mechanical and pharmacologic bridge to transplantation.ASAIO Trans1991; 37: M125–7
21.
SzucsT.D., SchrammW.. Die sozioökonomische Evaluation— Einführung in die Methodologie.Hamostaseologie1994; 14: 84–9
22.
PoirierV.L.. Can our society afford mechanical hearts?ASAIO-Trans1991; 37: 540–4
23.
LaheyS.J., BorlaseB.C., LavinP.T., LevitskyS.. Properative risk factors that predict hospital length of stay in coronary artery bypass patients ≥60 years old.Circulation1992; 86(Suppl 5): II181–5
24.
MatzukM.M., SchlomchikM., ShawL.M.. Making digoxin therapeutic drug monitoring more effective.Ther Drug Monit1991; 13: 215–9
25.
SchneiderJ.K., HornbergerS., BookerJ., DavisA., KralicekR.. A medication discharge planning program: measuring the effect on readmissions.Clin Nurs Res1993; 2: 41–53
26.
GoodwinD.R.. Critical pathways in home healthcare.J^ Nurs Adm1992; 22: 35–40
27.
KaneR.L., GarrardJ., BuchananJ.L., RosenfeldA., SkayC., McDermottS.. Improving primary care in nursing homes.J Am Geriatr Soc1991; 39: 359–67
28.
FonarowG.C., StevensonL.W., WaidenJ.A.Impact of a comprehensive management program on the hospitalization rate for patients with advanced heart failure. [Abstract].JACC199S (Special Issue): 264A
